Company: CDLX
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001666071-25-000069
Chunk: 100

Company: Cardlytics, Inc.
Filing Date: 2025-05-07
Form: 10-Q
Item: Item 1
Chunk 100
---
1,300,576)Total stockholders’ equity64,090 69,993 Total liabilities and stockholders’ equity$369,073 $392,711 

See notes to the condensed consolidated financial statements3

Table of Contents

CARDLYTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(Amounts in thousands, except per share amounts)

 Three Months EndedMarch 31, 20252024Revenue$61,898 $67,608 Costs and expenses:Partner Share and other third-party costs29,450 30,543 Delivery costs7,288 6,173 Sales and marketing expense12,754 14,118 Research and development expense11,706 13,048 General and administrative expense13,778 14,485 Change in contingent consideration60 5,817 Loss (gain) on disposal or divestiture(5,350)— Depreciation and amortization expense6,291 6,250 Total costs and expenses75,977 90,434 Operating Loss(14,079)(22,826)Other income (expense):Interest expense, net(1,830)(819)Foreign currency gain (loss)2,627 (630)Total other income (expense)797 (1,449)Loss before income taxes(13,282)(24,275)Net Loss$(13,282)$(24,275)Net Loss per share, basic and diluted$(0.26)$(0.56)Weighted-average common shares outstanding, basic and diluted51,863 43,248 

See notes to the condensed consolidated financial statements4

CARDLYTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)

(Amounts in thousands)

 Three Months EndedMarch 31, 20252024Net Loss$(13,282)$(24,275)Other Comprehensive (Loss) Income:Foreign currency translation adjustments(2,355)580 Total Comprehensive Loss$(15,637)$(23,695)

See notes to the condensed consolidated financial statements5

CARDLYTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (UNAUDITED)

(Amounts in thousands)

Three Months Ended March 31, 2025:

  AdditionalPaid-InCapitalAccumulatedOtherComprehensive Income (Loss)